The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesELISA: Use at a concentration of 0.5 µg/ml.
WB: Use at a concentration of 3 µg/ml, under non reducing or reducing conditions. Predicted molecular weight: 29 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionActs as a transcriptional regulator. Acts as a negative regulator of receptor-dependent signaling pathways. Specifically inhibits transactivation of the nuclear receptor with whom it interacts. Inhibits transcriptional activity of NEUROD1 on E-box-containing promoter by interfering with the coactivation function of the p300/CBP-mediated trancription complex for NEUROD1.
Tissue specificityLiver. Low levels of expression were detected in heart and pancreas.
Involvement in diseaseObesity
Sequence similaritiesBelongs to the nuclear hormone receptor family. NR0 subfamily.
Post-translational modificationsArginine methylation by PRMT5 enhances repression activity of metabolic genes in liver in response to bile acid signaling, by increasing interaction with cofactors.
Cellular localizationNucleus. Cytoplasm. Colocalizes with NEUROD1 in the nucleus.